Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cell Therapy for Early Functional Exhaustion of CAR-T Cells in r/r B-ALL
NCT06389305Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Randomised, double-blind trial of autologous cytokine-induced killer cells in B-cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Beijing Gaobo Hospital. Primary endpoint: Event-Free Survival at 2 years. Started May 2024; status: recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06389305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389305.